Clinical Trials Browser

INDUSTRY × Has results × ARQ 197 × Clear all

NCT01075048 2021-04-08

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Phase 1/2 Completed

131 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT01055067 2021-04-06

ARQ 197 for Participants With Relapsed or Refractory Germ Cell Tumors

Phase 2 Terminated

27 enrolled 6 charts

Seminoma

NCT01244191 2021-04-06

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

Phase 3 Terminated

1,048 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01755767 2021-04-06

METIV-HCC

Phase 3 Completed

383 enrolled 17 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT01178411 2021-03-10

An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols

Phase 1/2 Completed

60 enrolled 11 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms

NCT01395758 2018-04-03

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

96 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung